文献速递类风湿关节炎脊柱关节炎

戈利木单抗免疫原性及其在类风湿关节炎、银屑病关节炎和强直性脊柱炎患者中的临床相关性

Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

本研究开发了高灵敏度耐药酶免疫分析(DT-EIA)并交叉验证原EIA,重新检测了戈利木单抗皮下注射治疗类风湿关节炎、银屑病关节炎和强直性脊柱炎的三项3期试验样本。DT-EIA检测的抗药抗体(ADA)发生率较原EIA提高8倍(31.7% vs 4.1%),新检出ADA多为低滴度,高滴度(≥100)对戈利木单抗谷浓度影响更明显,但ADA对临床疗效或注射部位反应无影响。

要点

  • DT-EIA较原EIA显著提高ADA检出率(31.7% vs 4.1%)。
  • 新检出ADA多为低滴度,高滴度(≥100)对戈利木单抗谷浓度影响更明显。
  • ADA对临床疗效或注射部位反应无影响。

核心结论

  • 使用DT-EIA检测的ADA发生率高于原EIA,新检出ADA多为低滴度,对临床疗效或注射部位反应无影响,与原EIA结果一致。

研究设计与样本

  • 开发高灵敏度耐药EIA(DT-EIA)并与原EIA交叉验证,重新检测戈利木单抗皮下注射治疗类风湿关节炎、银屑病关节炎和强直性脊柱炎的三项3期试验样本。

主要发现

  • DT-EIA较原EIA更敏感,可在远高于免疫原性检测样本的戈利木单抗浓度下检测ADA。
  • DT-EIA检出ADA发生率为31.7%,原EIA为4.1%,提高8倍。
  • DT-EIA检出的ADA阳性患者大多抗体滴度较低,高滴度者大多原EIA已检出。
  • DT-EIA检测下ADA阳性患者戈利木单抗谷浓度通常低于ADA阴性患者,高滴度(≥100)时影响更明显。
  • ADA对临床疗效或注射部位反应无明显影响。

关键数值与推荐

  • ADA发生率:DT-EIA 31.7% vs 原EIA 4.1%。
  • 高ADA滴度定义为≥100。

临床怎么用

  • 临床解读戈利木单抗ADA时需注意检测方法敏感性差异,低滴度ADA可能无临床影响。
  • 高滴度ADA(≥100)与戈利木单抗谷浓度降低相关,但未发现对疗效或注射部位反应的影响。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Golimumab immunogenicity was extensively studied during clinical development. As anti-drug antibody (ADA) detection with the standard bridging EIA (original-EIA) can yield false-negative results or underestimate ADA incidence and titres due to drug interference, a more sensitive assay was needed to determine clinical impact. METHODS: A highly sensitive drug-tolerant EIA (DT-EIA) was developed and cross-validated against the original-EIA. Samples from phase-3 subcutaneous golimumab rheumatological trials (GO-FORWARD-rheumatoid arthritis, GO-REVEAL-psoriatic arthritis, GO-RAISE-ankylosing spondylitis) were then retested. Associations between ADAs and golimumab pharmacokinetics, efficacy and safety were assessed. RESULTS: The DT-EIA was more sensitive than the original-EIA and capable of detecting ADAs amid golimumab concentrations far exceeding those in immunogenicity test samples. Consequently, an 8-fold increase in the incidence of ADAs was observed with the DT-EIA (31.7%) vs original-EIA (4.1%) in the studies. Most ADA-positive patients identified by the DT-EIA had lower antibody titres, while most with higher titres were previously identified as ADA-positive by the original-EIA. With the DT-EIA, ADA-positive patients generally had lower trough serum golimumab concentrations than ADA-negative patients; however, ADA impact on serum golimumab concentrations was more notable at higher ADA titres (⩾100). No impact of ADAs on clinical efficacy or injection-site reactions was evident. CONCLUSION: ADA incidence was expectedly higher using the DT-EIA vs original-EIA; newly detected ADAs were characterized mostly by low titres, with no impact on clinical efficacy or injection-site reactions, consistent with previously observed original-EIA results. Golimumab immunogenicity with the DT-EIA is consistent with existing knowledge regarding the clinical relevance of ADAs detected with the original-EIA in patients with rheumatological disorders. TRIAL REGISTRATION: NCT00264550, NCT00265096, NCT00265083.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Leu JH, Adedokun OJ, Gargano C, et al. Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Rheumatology (Oxford). 2019. PMID: 30412238. doi:10.1093/rheumatology/key309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。